Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Aimmune Therapeutics (AIMT) PT Raised to $64 at Cantor Fitzgerald
-
Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
-
Aimmune Therapeutics Announces Closing of Public Offering of Common Stock
-
Aimmune Therapeutics (AIMT) Prices 5.5M Share Common Offering at $32/Sh
-
Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
-
Aimmune Therapeutics (AIMT) Offers $150M in Common Equity
-
Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Starts Aimmune Therapeutics (AIMT) at Overweight
-
Aimmune Therapeutics to Participate in Three Investor Conferences in September
-
Aimmune Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
